Open AccessInfluence of Pravastatin and Plasma Lipids on Clinical Events in the West of Scotland Coronary Prevention Study (WOSCOPS)
Author(s) -
All randomized patients were used to calculate quintiles of baseline LDL cholesterol,
HDL cholesterol,
and plasma triglyceride. The Kaplan-Meier -year risk of any cardiovascular event was then …,
both univariately and then multivariately with other baseline covariates as described in Reference,
to test their independence as predictors. The covariates used in the adjustment were age,
smoking,
blood pressure,
ECG abnormality,
self-reported angina,
self-reported hypertension,
diabetes,
family history of premature death from CHD,
and nitrate use.
Publication year - 1998
Publication title -
circulation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 7.795
H-Index - 607
eISSN - 1524-4539
pISSN - 0009-7322
DOI - 10.1161/01.cir.97.15.1440
Subject(s) - pravastatin , medicine , cohort , placebo , cholesterol , proportional hazards model , incidence (geometry) , hydroxymethylglutaryl coa reductase , cohort study , coronary heart disease , cardiology , endocrinology , hmg coa reductase , reductase , biochemistry , chemistry , physics , alternative medicine , pathology , optics , enzyme
The West of Scotland Coronary Prevention Study was a primary prevention trial that demonstrated the effectiveness of pravastatin (40 mg/d) in reducing morbidity and mortality from coronary heart disease (CHD) in moderately hypercholesterolemic men. The present analysis examines the extent to which differences in LDL and other plasma lipids both at baseline and on treatment influenced CHD risk reduction.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom